Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss.
MAPK
NF-κB
Nrf2
osteoclastogenesis
pristimerin
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
10
2020
accepted:
07
12
2020
entrez:
25
2
2021
pubmed:
26
2
2021
medline:
26
2
2021
Statut:
epublish
Résumé
Osteoporosis is characterized by bone loss and destruction of trabecular architecture, which greatly increases the burden on the healthcare system. Excessive activation of osteoclasts is an important cause of osteoporosis, and suppression of osteoclastogenesis is helpful for the treatment of osteoporosis. Pristimerin, a natural compound, possesses numerous pharmacological effects via inactivating the NF-κB and MAPK pathways, which are closely related to osteoclastogenesis process. However, the relationship between Pristimerin and osteoclastogenesis requires further investigation. In this research, we examined the effect of Pristimerin on osteoclastogenesis and investigated the related mechanisms. Our results showed Pristimerin inhibited RANKL-induced osteoclast differentiation and osteoclastic bone resorption
Identifiants
pubmed: 33628184
doi: 10.3389/fphar.2020.621110
pii: 621110
pmc: PMC7898668
doi:
Types de publication
Journal Article
Langues
eng
Pagination
621110Informations de copyright
Copyright © 2021 Qi, Liu, Sun, Luo, Zhu, Tao, Gao, Zhou, Zhou and Xiao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Physiology (Bethesda). 2016 May;31(3):233-45
pubmed: 27053737
Cell Mol Life Sci. 2007 Sep;64(18):2334-50
pubmed: 17530461
J Cell Mol Med. 2019 Nov;23(11):7545-7553
pubmed: 31508890
J Clin Invest. 2005 Feb;115(2):200-8
pubmed: 15690073
Evid Based Complement Alternat Med. 2012;2012:340787
pubmed: 22675379
Arch Pharm Res. 2013 Apr;36(4):495-500
pubmed: 23435916
Front Immunol. 2019 Apr 03;10:679
pubmed: 31001277
J Biomed Sci. 2015 Oct 29;22:101
pubmed: 26511009
Nature. 2003 May 15;423(6937):337-42
pubmed: 12748652
Biomaterials. 2018 Dec;185:25-38
pubmed: 30216807
Ann Intern Med. 2017 Aug 1;167(3):ITC17-ITC32
pubmed: 28761958
Dev Cell. 2002 Dec;3(6):889-901
pubmed: 12479813
Cell Biochem Funct. 2018 Jun;36(4):228-240
pubmed: 29781107
Ann N Y Acad Sci. 2011 Dec;1240:E13-8
pubmed: 22360322
Curr Osteoporos Rep. 2019 Jun;17(3):97-104
pubmed: 30915637
Int Immunopharmacol. 2014 Aug;21(2):501-8
pubmed: 24957686
Pest Manag Sci. 2005 Jan;61(1):85-90
pubmed: 15593077
J Dent Res. 2013 Oct;92(10):860-7
pubmed: 23906603
Bone Res. 2018 Mar 30;6:9
pubmed: 29619269
Clin Rev Allergy Immunol. 2016 Aug;51(1):1-15
pubmed: 26411424
Clin Immunol. 2014 Dec;155(2):220-30
pubmed: 25308129
Toxins (Basel). 2010 Oct;2(10):2428-66
pubmed: 22069560
Nutr Rev. 2007 Dec;65(12 Pt 2):S147-51
pubmed: 18240539
Molecules. 2010 Oct 11;15(10):6956-73
pubmed: 20938406
Nat Rev Endocrinol. 2010 Nov;6(11):629-36
pubmed: 20820194
Phytomedicine. 2018 Feb 1;40:140-147
pubmed: 29496166
Front Pharmacol. 2019 Jul 12;10:746
pubmed: 31354475
Int J Mol Sci. 2019 Jul 22;20(14):
pubmed: 31336616
Redox Biol. 2020 Jan;28:101309
pubmed: 31487581
Biochim Biophys Acta Mol Cell Res. 2018 May;1865(5):721-733
pubmed: 29499228
Cancer Manag Res. 2018 Dec 19;11:47-61
pubmed: 30588110
Trends Mol Med. 2006 Jan;12(1):17-25
pubmed: 16356770
J Cell Physiol. 2019 Jul;234(7):11009-11022
pubmed: 30548260
Int J Oncol. 2014 May;44(5):1707-15
pubmed: 24603988
J Nat Prod. 1998 Jun 26;61(6):718-23
pubmed: 9644053
J Biol Chem. 2009 Jan 23;284(4):2584-92
pubmed: 19028686
Antioxid Redox Signal. 2018 Dec 10;29(17):1727-1745
pubmed: 28899199
Immunopharmacol Immunotoxicol. 2016 Jun;38(3):221-7
pubmed: 27098091
Int Immunopharmacol. 2018 Jun;59:31-39
pubmed: 29621734
Trends Mol Med. 2014 Aug;20(8):449-59
pubmed: 25008556
Front Immunol. 2014 Oct 20;5:511
pubmed: 25368616
Biochem Med (Zagreb). 2013;23(1):43-63
pubmed: 23457765
Annu Rev Pathol. 2011;6:121-45
pubmed: 20936937
Neurotox Res. 2018 Feb;33(2):268-283
pubmed: 29119451
Histochem Cell Biol. 2018 Apr;149(4):325-341
pubmed: 29392395
Cancer Lett. 2017 Feb 28;387:95-105
pubmed: 27037062
Nat Rev Mol Cell Biol. 2007 Oct;8(10):813-24
pubmed: 17848967
Curr Opin Rheumatol. 2018 Jan;30(1):59-64
pubmed: 29016371
FASEB J. 2015 Mar;29(3):1092-101
pubmed: 25466887
Front Pharmacol. 2018 Mar 28;9:292
pubmed: 29643811
Int Immunopharmacol. 2015 Dec;29(2):302-313
pubmed: 26548348
Antioxid Redox Signal. 2014 Mar 1;20(7):1126-67
pubmed: 23991888